Archivio

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Dolutegravir-based HIV treatment is better for babies and young children

Probability of AIDS and non-AIDS-related mortality of early-treated children living with HIV-1

Symptom presentation among SARS-CoV-2 positive cases and the impact of COVID-19 vaccination; three prospective household cohorts

Joint evolution of CD4 and viral load trajectories over 2 years in an early-treated pediatric African cohort

Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy

Incidence of SARS-CoV-2 infection and clinical characteristics in children and young people living with HIV in Europe

Incidence of SARS-CoV-2 infection and clinical characteristics in children and young people living with HIV in Europe

Registrations are open for the PentaTr@ining course: ‘Fungal Infections in Paediatrics’

CARMA Global sites prepared and ready to enrol

Population pharmacokinetics of unbound and total plasma dolutegravir concentrations in children ≥ 12 years old: A pharmacokinetic sub-study of the SMILE trial-PENTA17-ANRS 152

Effect of dolutegravir on folate and vitamin B12 status among HIV- infected children and adolescents in the ODYSSEY trial

The subphenotypes of early-treated children living with HIV-1

ZIKAction paediatric registry: maternal characteristics and clinical, radiological, and follow-up features of children born with congenital zika infection in brazil